Skip to content

Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals

Drummond E-Wen Mcculloch, Martin Bruun Madsen, Dea Siggaard Stenbæk, Sara Kristiansen, Brice Ozenne, P.s. Jensen, Gitte M. Knudsen, Patrick M. Fisher

Journal of Psychopharmacology June 30, 2021 DOI: 10.1177/02698811211026454 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational cohort Peer reviewed
Sample size 10
Population Healthy psychedelic-naïve volunteers
Intervention Psilocybin
Dose 0.2–0.3 mg/kg
Duration 3-month follow-up
Topics Psilocybin
Keywords Functional connectivity Resting State FMRI Hallucinogen
Citations 79
Key findings A single psilocybin dose decreased executive control network resting-state functional connectivity at one week, and this decrease predicted increased mindfulness at three months.

Abstract

Background: Psilocybin is a psychedelic drug that has shown lasting positive effects on clinical symptoms and self-reported well-being following a single dose. There has been little research into the long-term effects of psilocybin on brain connectivity in humans.

Aim: Evaluate changes in resting-state functional connectivity (RSFC) at 1 week and 3 months after one psilocybin dose in 10 healthy psychedelic-naïve volunteers and explore associations between change in RSFC and related measures.

Methods: Participants received 0.2–0.3 mg/kg psilocybin in a controlled setting. Participants completed resting-state functional magnetic resonance imaging (fMRI) scans at baseline, 1-week and 3-month post-administration and [11C]Cimbi-36 PET scans at baseline and 1 week. We examined changes in within-network, between-network and region-to-region RSFC. We explored associations between changes in RSFC and psilocybin-induced phenomenology as well as changes in psychological measures and neocortex serotonin 2A receptor binding.

Results: Psilocybin was well tolerated and produced positive changes in well-being. At 1 week only, executive control network (ECN) RSFC was significantly decreased (Cohen’s d = −1.73, pFWE = 0.010). We observed no other significant changes in RSFC at 1 week or 3 months, nor changes in region-to-region RSFC. Exploratory analyses indicated that decreased ECN RSFC at 1 week predicted increased mindfulness at 3 months ( r = −0.65).

Conclusions: These findings in a small cohort indicate that psilocybin affects ECN function within the psychedelic ‘afterglow’ period. Our findings implicate ECN modulation as mediating psilocybin-induced, long-lasting increases in mindfulness. Although our findings implicate a neural pathway mediating lasting psilocybin effects, it is notable that changes in neuroimaging measures at 3 months, when personality changes are observed, remain to be identified.

Comparable studies

Other observational and cohort studies on psilocybin, most cited first.

Study Year Design Participants
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Patients with treatment-resistant depression 2017 Observational cohort n = 19
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels Healthy volunteers 2019 Observational cohort n = 8
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin Humans 2017 Observational study
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. USA adult respondents from the National Survey on Drug Use and Health (2008-2012) 2015 Observational cohort n = 190,000
Prediction of Psilocybin Response in Healthy Volunteers Healthy volunteers 2012 Observational cohort n = 409

Citations in the library

Explore topics